Secukinumab

Details

Files

Generic Name:

Secukinumab

Project Status:

Complete

Therapeutic Area:

Plaque psoriasis

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Call for patient/clinician input open:

November 5, 2014

Brand Name:

Cosentyx

Project Line:

Reimbursement Review

Project Number:

SR0407-000

Call for patient/clinician input closed:

December 24, 2014

NOC Status at Filing:

Pre NOC

Performance Metric:

Not achieved

Submission Type:

Initial

Indications:

Psoriasis, moderate to severe plaque

Recommendation Type:

List with criteria/condition

Final Recommendation:

October 28, 2015

Files

Recommendation and Reasons: Updated View PDF

Submission Status Report View PDF

Recommendation and Reasons: Original View PDF

Clinical Report View PDF

Pharmacoeconomic Report View PDF

Patient Group Input Submissions View PDF

Last Updated : December 8, 2014